Please login to the form below

Not currently logged in
Email:
Password:

Teva's US approval for hypertension drugs

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure drugs Cozaar and Hyzaar

Teva Pharmaceutical has won US approval for its generic versions of Merck's blockbuster blood-pressure (hypertension) drugs Cozaar (losartan) and Hyzaar (hydrochlorothiazide and losartan), and intends to launch sales immediately.

Teva, the world's biggest generic drug producer, will have 180 days to market the generics exclusively, an award generally given to companies that challenge patents first.

An exclusivity period can allow generic companies a window of significant sales before rivals rush in and pricing freefalls.

Teva said a federal appeals court this week rejected an effort by generic drug producers Apotex and Roxane Laboratories to challenge Teva's right to that exclusivity period.

Last week, Apotex and Roxane sued the US Food and Drug Administration, arguing that a key patent for the drugs had expired and therefore no company was eligible for the exclusive rights.

Cozaar and Hyzaar, which have annual US sales of about $1.6bn, have been among Merck's biggest selling products, but the pharma company has been bracing for generic competition this year.

8th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics